e-learning
resources
Stockholm 2002
Sunday 15.09.2002
Asthma and COPD: pharmacology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction
J. M. Wraight, A. D. Smith, J. O. Cowan, E. M. Flannery, G. P. Herbison, D. R. Taylor (Dunedin, New Zealand)
Source:
Annual Congress 2002 - Asthma and COPD: pharmacology
Session:
Asthma and COPD: pharmacology
Session type:
Thematic Poster Session
Number:
752
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. M. Wraight, A. D. Smith, J. O. Cowan, E. M. Flannery, G. P. Herbison, D. R. Taylor (Dunedin, New Zealand). Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction. Eur Respir J 2002; 20: Suppl. 38, 752
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Nighttime short-acting beta-agonist (SABA) in asthma and COPD
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Year: 2019
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β
2
agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol
Source: International Congress 2019 – Airway physiology
Year: 2019
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β
2
-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells
Source: Eur Respir J 2003; 22: Suppl. 45, 35s
Year: 2003
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Source: Eur Respir J 2001; 17: 368-373
Year: 2001
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Source: Eur Respir J 2007; 30: 653-661
Year: 2007
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level
Source: International Congress 2015 – COPD: notable points
Year: 2015
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Inhaled corticosteroids and growth of airway function in asthmatic children
Source: Eur Respir J 2004; 23: 861-868
Year: 2004
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Comparison of long acting β
2
-agonist inhalers for treatment of exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2003; 22: Suppl. 45, 312s
Year: 2003
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006
COPD and airway responsiveness to beta-agonists
Source: Annual Congress 2007 - Airway regulation, provocation and monitoring - III
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept